Propofol-Lipuro

국가: 아르메니아

언어: 영어

출처: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

유효 성분:

propofol

제공처:

B.Braun Melsungen AG

INN (국제 이름):

propofol

복용량:

10mg/ml

약제 형태:

emulsion for i/v injection

처방전 유형:

Prescription

제품 특성 요약

Propofol
l0
mg
Excipients
rryith
known
effect:
200
mg
500
mg
I
ml
emulsion
for
injection
or
infusion
contains
Soya-bean
oil,
refined
50
mg
Sodium
0.03
mg
For
the
full
list
ofexcipients,
see
section
6.1.
4.1
Therapeuticindications
Propofol-Lipuro
l0
mg/ml
is
a
short-acting
intravenous
general
anaesthetic
for
o
inductibn
and
maintenance
ofgeneral
anaesthesia
in
adults
and
children
>
I
month
o
sedation
ofventilated
patients->l6
years
ofage
in
the
intensive
care
unit
-
o
sedation
for
diagnostii
and
surgical
procedures, alone
or
in
combination
with
local
or
regional
anaesthesia
in adults
and
children
>
I
month.
4.2
Posolory
and
Method
of
Administration
General
instructions
propofol-Lipuro
l0
mg/ml
must
only
be
given in
hospitals
or
adequately
equipped
day
therapy
units
Uy
physicians
trained
in
anaesthesia
or
in
the
care
of
patients
in
intensive
care.
Circulatory
and
respi-
.atory
functions
should
be
constantly
monitored
(e.g.
ECG,
pulse-oxymeter)
and
facilities
for
mainte-
nance
ofpatent
airways,
artificial
ventilation,
and
other
resuscitation
facilities
should
be
immediately
available
at
all
times.
For
sedation
during
surgical
or
diagnostic
procedures
Propofol-Lipuro
l0
mg/ml
shotrld
not
be
given
by
the
same
person
that
carries
out
the surgical
or
diagnostic
procedure.
Supplementary
analgesic
medicinal
products are
generally
required
in addition
to
Propofot-Lipuro
l0
mg/ml.
- B.
Bdun
Mcbngo
AC
rDE-
Posologlt
Propofol-Lipuro
l0
mg/ml
is
given
intravenously.
The
dosage
is
adjusted
individually
according to
the
patient's
response.
o
General anaesthesia in
adults
Induction
of
anaesthesia:
For
induction
of
anaesthesia
Propofol-Lipuro
I
0
mg/ml
should
be
titrated
(20
-
40 mg
of
propofol
every
l0
seconds)
against the
patient's
response
until
the
clinical
signs
show the onset
ofanaesthesia.
Most
adult
patients younger
than
55
years
are
likely
to
require
1.5
to
2.5
mg/kg
body
weight.
In
patients
over
this
age
and
in
patients
of
ASA
grades
III
and
IV,
especially
those
with
impaired car-
diac
function,
the
dosage
requirements
r